106 related articles for article (PubMed ID: 17960380)
1. Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Oshita F; Yamada K; Saito H; Noda K
Cancer Chemother Pharmacol; 2008 Aug; 62(3):465-70. PubMed ID: 17960380
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.
Oshita F; Yamada K; Saito H; Noda K; Hamanaka N; Ikehara M
J Exp Ther Oncol; 2004 Dec; 4(4):343-8. PubMed ID: 15844664
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
4. Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.
Oshita F; Saito H; Yamada K
J Exp Ther Oncol; 2007; 6(3):251-6. PubMed ID: 17552365
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
Oshita F; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):345-50. PubMed ID: 23124649
[TBL] [Abstract][Full Text] [Related]
6. Nedaplatin and irinotecan with concurrent thoracic radiotherapy followed by docetaxel consolidation in patients with locally advanced non-small cell lung cancer.
Oshita F; Murakami S; Kondo T; Saito H; Yamada K; Nakayama Y
J Exp Ther Oncol; 2017 May; 12(1):17-23. PubMed ID: 28472560
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer.
Oshita F; Murakami S; Kondo T; Saito H; Yamada K
J Exp Ther Oncol; 2013; 10(3):203-8. PubMed ID: 24416995
[TBL] [Abstract][Full Text] [Related]
8. Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.
Ohe M; Oshita F; Kenmotsu Y; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
J Exp Ther Oncol; 2012; 10(1):65-9. PubMed ID: 22946345
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.
Oshita F; Ohe M; Honda T; Murakami S; Kondo T; Saito H; Noda K; Yamashita K; Nakayama Y; Yamada K
Br J Cancer; 2010 Oct; 103(9):1325-30. PubMed ID: 20940720
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Oshita F; Saito H; Murakami S; Kondo T; Yamada K
Am J Clin Oncol; 2010 Feb; 33(1):66-9. PubMed ID: 19786849
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.
Yamada K; Saito H; Kondo T; Murakami S; Masuda N; Yamamoto M; Igawa S; Katono K; Takiguchi Y; Iwasawa S; Kurimoto R; Okamoto H; Shimokawa T; Hosomi Y; Takagi Y; Kishi K; Ohba M; Oshita F; Watanabe K
Anticancer Res; 2015 Dec; 35(12):6705-11. PubMed ID: 26637886
[TBL] [Abstract][Full Text] [Related]
12. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
13. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Yu S; Zhang B; Xiang C; Shu Y; Wu H; Huang X; Yu Q; Yin Y; Guo R
Clin Lung Cancer; 2015 Mar; 16(2):121-7. PubMed ID: 25450874
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.
Oshita F; Honda T; Murakami S; Kondo T; Saito H; Noda K; Yamada K
J Thorac Oncol; 2011 Jan; 6(1):128-31. PubMed ID: 21150472
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Oshita F; Noda K; Nishiwaki Y; Fujita A; Kurita Y; Nakabayashi T; Tobise K; Abe S; Suzuki S; Hayashi I; Kawakami Y; Matsuda T; Tsuchiya S; Takahashi S; Tamura T; Saijo N
J Clin Oncol; 1997 Jan; 15(1):304-9. PubMed ID: 8996157
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
[TBL] [Abstract][Full Text] [Related]
19. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
